Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of CARTs, CTLs and DC Vaccines Targeting Melanoma
NCT06739226Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2028
- Modality
- Whole Cell Cancer Vaccines, CAR-T Cells, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Trivirus-specific cytotoxic T-lymphocytes and WT1/hTERT/Survivin-loaded dendritic cell vaccine in melanoma, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Number of patients with adverse events at 1 year. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
Trivirus-specific cytotoxic T-lymphocytesWT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06739226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739226.